Group 1 - Avidity Biosciences (NASDAQ:RNA) has announced new data from its clinical trials evaluating the experimental treatment del-zota for Duchenne muscular dystrophy [4] - After one year of continuous treatment, participants showed not only a halt in disease progression, but also measurable improvements compared to their baseline [5]